# An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)

> **NCT02675998** · PHASE3 · COMPLETED · sponsor: **Ardelyx** · enrollment: 219 (actual)

## Conditions studied

- Hyperphosphatemia

## Interventions

- **DRUG:** Tenapanor
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02675998
- **Lead sponsor:** Ardelyx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-12
- **Final completion:** 2018-01-17
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2020-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02675998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02675998, "An 8-Week Study to Evaluate Tenapanor in the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients on Hemodialysis (ESRD-HD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02675998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*